MedDataX Logo

Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge).

NCT ID: NCT02553954

Last Updated: 2021-10-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-07

Study Completion Date

2020-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidemiological data show that the incidence of carcinoma, the most common cancer, is strongly linked to the age. Non Melanoma Skin Carcinomas (NMSCs) (the most frequent cancers in the elderly population) derive from keratinocytes of the basal layer of the epidermis, from differentiated keratinocytes of the more superficial layers or from stem cells of hair follicles. Unlike NMSCs, soft-tissue sarcomas, including those deriving from dermal fibroblasts, are very rare (less than 1% of all cancers). Our overall purpose is to decipher the molecular pathways activated during the aging of these tissues that may explain why they have a so different propensity to undergo a malignant transformation. Given that senescent cells accumulate in the dermis and epidermis with age, we will constitute two groups : "young skin" that we arbitrarily limit to the range ≥ 18 and ≤ 40 and "aged skin" ≥ 55.

Thus the main objective of our study is to search within 2 age groups (≥ 18 and ≤ 40 years and ≥ 55 years) the expression of senescence markers on healthy skin tissue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Information and obtaining informed consent.
* Collection of clinical data.
* Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a sarcoma.
* Freezing samples of healthy skin tissue in liquid nitrogen within 10 minutes after collection.
* Transfer of the samples to the laboratory of anatomopathology.
* Preparation of the healthy skin samples by the laboratory of anatomopathology.
* Transfer of the conditioned samples to the Institut de Biologie de Lille for analysis.
* Control of the aesthetic appearance during the postoperative consultation.
* Destruction of the samples at the end of analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Collection of healthy skin tissue

Collection of healthy skin tissue

Group Type EXPERIMENTAL

Collection of healthy skin tissue

Intervention Type PROCEDURE

Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collection of healthy skin tissue

Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with an operable sarcoma
* Requiring a surgical operation under general anesthesia at the Oscar Lambret Centre
* Age ≥ 18 ans, belonging to one of the two following age groups : \[ ≥ 18 and ≤ 40 years\] and \[ ≥ 55 years\]
* Patient having a social security scheme
* Patient having signed an informed consent form for the study

Exclusion Criteria

* Patient aged under 18 or between 41 and 54
* Location of the tumor on the face, neck or neckline
* Patient with a skin tumor
* Tumor-induced cutaneous fistula making suspect a tumor invasion of the skin
* Patient with a chronic skin disease
* Collection in an area already treated by surgery, radiotherapy or brachytherapy
* Pregnant or breastfeeding women
* Patient under guardianship or tutorship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut de Biologie de Lille

OTHER

Sponsor Role collaborator

Centre Oscar Lambret

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicolas PENEL, MD

Role: STUDY_CHAIR

Centre Oscar Lambret

Olivier PLUQUET

Role: STUDY_DIRECTOR

Institut de Biologie de Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Oscar Lambret

Lille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-A01793-42

Identifier Type: OTHER

Identifier Source: secondary_id

SkinAge-1306

Identifier Type: -

Identifier Source: org_study_id